57 results about "Diabetes mellitus type II" patented technology

The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and / or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and / or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.

The invention relates to thiadiazole derivatives which are shown as a formula I and have DPP-IV (dipeptidyl peptidase IV) inhibition activity, a preparation method of the thiadiazole derivatives and drug compositions of the thiadiazole derivatives, and application of the thiadiazole derivatives to treatment of diseases beneficial from DPP-IV inhibition, especially application to treatment of diabetes mellitus type 2. The thiadiazole derivatives provided by the invention have very good DPP-IV inhibition activity, have a very good in-vivo metabolic level and a very proper in-vivo half-life period and are expected to be used as proper DPP-IV inhibitor drugs.

The invention refers to the herbal composition which consists of: the plant of centaury (Centauri herba) 12.3% by wt., the root of dandelion (Teraxaci radix) 9.7% by wt., the fruit of juniper (Juniperi communis fructus) 6.2% by wt., the plant of nettle (Urticae herba) 7.4% by wt., the root of nettle (Urticae radix) 7.0% by wt., the root of chicory (Cichorii radix) 17.7% by wt., the leaf of black mulberry (Morus nigra folium) 7.4% by wt., the flower of yarrow (Achilleae millefolii flos) 3.5% by wt., the leaf of bilberry (Vaccinii myrtilli folium) 6.6% by wt., the pod of beans (Phaseoli fructus sine semeni) 14.4% by wt., and the root of valerian (Valerianae officinalis radix) 7.8% by wt., and to the medicament against diabetes mellitus type II obtained from it. The medicament is anticipated to be administered perorally in form of tea, a tincture and a pill.

The present invention relates to compounds having a decaline scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and / or diluents. Said decaline-derived compounds can be used for prophylaxsis and / or treatment of diabetes mellitus type I, diabetes mellitus type II, tuberculosis and other infectious diseases, proliferative diseases, cancer, neurodegenerative diseases, obesity, cognitive dysfunctions and metabolic syndromes.

An active substance is extracted from an herbal composition which comprises: Centaurii umbellatum, Gentianaceae (centaury plant), Teraxacum officinale, Asteraceae (dandelion root), Juniperi communis L, Cupresaceae (juniper berry), Urticae dioica L, Urticeae (nettle plant), Urticae dioica L, Urticaceae (nettle root), Cichorium intybus L, Cichoriaceae (chicory root), Morus nigra L, Moraceae, (mulberry leaf), Achilleae millefolium L, Asteraceae (yarrow flower), Vaccinium myrtillus L, Ericaceae (bilberry leaf), Phaseolus vulgaris L, Fabaceae (bean pods), Valeriana officinalis L, Valerlanaceae (Valerian root). The active substance is used in the manufacture of pharmaceutical compositions used in connection with control of diabetes mellitus type II.

The invention discloses new application of mogroside extract, and particularly relates to application of mogroside extract to preparation of an alpha-glucosidase inhibitor. The research indicates that the mogroside extract has a certain inhibiting effect on alpha-glucosidase, the inhibiting effect on alpha-glucosidase is of a mixed type, and mogroside extract has a strong static quenching effect on alpha-glucosidase endogenous fluorescence. It is indicated that the mogroside extract can be applied to preparation of food, healthcare food and drugs for treatment or adjuvant treatment on diabetes mellitus type II.

The invention relates to a novel sulfonamide compound in a structure of a general formula I as shown in the specification, or pharmaceutically acceptable salt and a preparation method of the novel sulfonamide compound, and further relates to a drug composition containing the compound as shown as the general formula I or the pharmaceutically acceptable salt of the compound, and a use of the compound or the pharmaceutically acceptable salt for preparing a drug for preventing and / or treating symptoms or diseases such as hyperglycemia and diabetes mellitus type 2 since the compound as shown as the general formula I or the pharmaceutically acceptable salt of the compound has activity of inhibiting a protein tyrosine phosphatase 1B (PTP 1B).

The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.

The invention provides a composition for constructing an animal model of diabetes mellitus type II and application of the composition to preparing feeds or drugs for constructing the animal model of the diabetes mellitus type II, wherein the composition comprises a conjugated linoleic acid mixture of which the weight percentage is more than 0.1% relative to the composition; and the animal model of the diabetes mellitus type II is prepared by feeding the composition to the mouse. Because the conjugated linoleic acid mixture or a single conjugated linoleic acid monomer is adopted as an inducer and the mouse is adopted as the animal protomodel, compared with a traditional chemical drug or diet induced animal model of the diabetes mellitus type II, the composition provided by the invention has the advantages of low price, convenience and easiness for raw material obtaining; and because the model establishing time is 4-6 weeks, the period is short, the formed model is characterized by hyperglycemia, high insulin level and in-vivo insulin resistance, the composition accords with basic characteristics of the diabetes mellitus type II and is an ideal composition for constructing the animal model of the diabetes mellitus type II.

The invention relates to the field of medicine, in particular to a mirabilis jalapa root general flavone extractive for preventing and curing diabetes mellitus type 2 and a preparation method and application thereof. In the extractive, the content of general flavone is greater than 40%, when the dosage of the extractive is 100 mg / kg, the extractive has obvious effects on decreasing the content ofblood glucose, total cholesterol, triglycerides, tissue triglycerides and increasing glycogen content, prophylaxis and remedial medication have similar effects on blood glucose and lipid lowering of diabetes mellitus type 2 induced by streptozotocin, also reduce blood glucose and lipid type 2 diabetes (db / db) mice of gene knockout, and do not affect glucolipid metabolism of normal mice. Accordingto the preparation method of mirabilis jalapa root general flavone extractive, mirabilis jalapa root general flavone is separated and purified by macroporous adsorption resin, in the prepared mirabilis jalapa root general flavone extractive, the content of the general flavone is greater than 40 %, the transfer rate reaches up to 70 %, and the yield rate can reach up to 2 %.

The invention relates to a dietary supplement comprising alpha keto acids for supporting diabetes therapy. The invention relates to a preparation used as a dietary supplement comprising alpha keto acids for supporting therapy of diabetes mellitus type II (DM). The preparation comprises at least one of the alpha keto acids from the group alpha ketoisocaproate (KIC), alpha ketoisovalerate (KIV), alpha keto beta methylvalerate (KMV) and alpha keto glutarate (AKG).

The invention relates to a GLP-1 analogue derivative modified with a DPP4 inhibitor and analogue thereof. The derivative has a longer half-life period than marketed GLP-1 medicine, such as exenatide and liraglutide, and has interesting pharmaceutical properties in treatment of diabetes mellitus type 2.

The invention relates to an N2-glycosyl-substituted 1,2,3-triazole compound and a synthesis method and application thereof. The general structural formula of the N2-glycosyl-substituted 1,2,3-triazole compound is shown in the specification, wherein R1 indicates H atoms or halogen atoms or alkyl groups of 1-6 carbon atoms or alkoxy groups of 3-10 carbon atoms or aryl groups or heterocyclic groups or benzoyl groups or formyloxy groups or cyano groups, and R indicates hydrogen or alkyl groups or halogen atoms or nitro groups or alkoxy groups or cyano groups and is located at ortho-position, meta-position and para-position single substitution or polysubstitution of aromatic rings. The N2-glycosyl-substituted 1,2,3-triazole compound and the synthesis method and application thereof have the advantages that synthesis conditions are easy to control, the yield is high, and the cost is low; application of triazole derivatives in the fields of pesticide, medicine, food and the like is further promoted; a new way is provided for research and development of high-value utilization and modification of triazole; the compound has high inhibiting ability for alpha-glucosidase and can be further developed into medicine used for treating or assisting in treating diabetes mellitus type 2.

The present invention relates to the novel use of an extract from a Cimicifuga species, preferably Cimicifuga racemosa (also termed Actaea racemosa L; black cohosh). In particular, the invention is directed to an extract from Cimicifuga sp., preferably Cimicifuga racemosa, for use in the therapeutic or prophylactic treatment of diabetes, preferably diabetes mellitus type 2, the use of such extracts for preparing a medicament, corresponding pharmaceutical compositions comprising the extract as well as a method for the therapeutic or prophylactic treatment of diabetes, preferably by oral administration of the extract or pharmaceutical composition.

Described are positive allosteric modulators of the GLP-1 receptor, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for diabetes mellitus type 2, obesity, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, cognitive dysfunction, learning disability, and asthma in a subject.

The invention relates to a functional nutritional powder composition suitable for patients with diabetes mellitus type II. The functional nutritional powder composition is prepared from the following raw materials by weight percent: 20-50% of soybean protein, 1-10% of whey protein, 15-35% of skim milk powder, 8-30% of konjac flour, 10-40% of beer yeast, 5-30% of resistant maltodextrin and sucralose. The functional nutritional powder composition can provide high-quality and complete protein, complete B-vitamin group, fourteen life-bound high-quality minerals, trace elements and high-quality functional dietary fibers. The functional nutritional powder composition supplements the nutritional components needed by special groups, controls the intake of carbohydrate, increases satiety, balances dietary structure and reduces kidney burden; the functional nutritional powder composition has the effects of adjusting blood glucose as well as preventing and treating early and middle stage of diabetes mellitus type II by repairing pancreas islets function and insulin receptor binding ability.

The invention relates to corylin compositions for treating or preventing any one or more of hyperlipemia, hyperglycemia, nonalcoholic fatty liver and diabetes mellitus type 2; the compositions can be prepared into medicines, health foods or functional foods; excipients or carriers used for the compositions are excipients or carriers such as diluents, disintegrating agents and lubricating agents which are commonly used in the field of pharmacy or food.

The invention relates to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridine-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and / or type 1.

The invention provides a preparing method for alogliptin benzoate, and particularly provides a method for preparing 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]methyl]benzonitrile monobenzoate shown as a formula (I). The compound is a novel medicine treating diabetes mellitus type 2. The alogliptin benzoate (HPLC purity of which is greater than 99.95%) can be prepared in a high yield and high purity by the method, a process is simple and convenient to operate and the method is suitable for industrial production.

The invention is concerned with use of oral inorganic pyrophosphate for preventing and / or reducing tissue calcification, particularly soft tissue calcification, and / or diseases or disorders characterized by low plasma PPi levels, as, e.g., occurs in chronic kidney disease (CKD), end-stage renal disease (ESRD), generalized arterial calcification of infancy (GACI), Pseudoxanthoma elasticum (PXE), Arterial Calcification Due to Deficiency of CD73 (ACDC), Ehlers-Danlos syndrome, arteriosclerosis obliterans, venous calcifications, crystal deposition disorders, calcification resulting from neurological disorders, calcinosis universalis, calcinosis circumscripta, scleroderma, dermatomyositis, systemic lupus erythematosus, hyperparathyroidism, neoplasms, milk-alkali syndrome, hypervitaminosis D, tumoral calcinosis, hypophosphatemic rickets, ossification of the posterior longitudinal ligament of the spine, myocardial ischemia, joint calcification, heterotropic ossification of traumatized muscle, angioid streaks, diabetes mellitus type II, cardiovascular disorder, or atherosclerosis.

The invention relates to thiadiazole derivatives which are shown as a formula I and have DPP-IV (dipeptidyl peptidase IV) inhibition activity, a preparation method of the thiadiazole derivatives and drug compositions of the thiadiazole derivatives, and application of the thiadiazole derivatives to treatment of diseases beneficial from DPP-IV inhibition, especially application to treatment of diabetes mellitus type 2. The thiadiazole derivatives provided by the invention have very good DPP-IV inhibition activity, have a very good in-vivo metabolic level and a very proper in-vivo half-life period and are expected to be used as proper DPP-IV inhibitor drugs.

The invention discloses chalcone derivatives containing allyl structures, and application of the chalcone derivatives. 39 novel allyl-progeny steranes, based on licochalcone A and E used as pre-molecules are synthesized. As a PTP1B inhibitor, the chalcone derivatives can improve the treatment of common diabetes mellitus type 2. Most synthetic compounds show potent inhibition on PTP1B.

The invention discloses benzopyran compounds as shown in a formula I, a preparation method of the benzopyran compounds, a composition containing the compounds, and use of the compounds in preparation of a farnesoid X receptor antagonist, a liver protection agent and medicines for preventing and treating hyperlipidemia and diabetes mellitus type II.

The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.

Disclosed is a use of Helminthostachys zeylanica, ugonins or compounds of formula (I) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.

The invention belongs to the technical field of preparation of medicine for treating diabetes, and discloses an amino polyethylene glycol functionalized nano graphene oxide supported insulin derivative material, a preparation method thereof and application thereof in preparation of the medicine for treating diabetes mellitus type 2. The material is prepared through the method including the following steps: adding amino polyethylene glycol into a graphene oxide solution, then adding 1-ethyl-(3-dimethyl aminopropyl) carbonyl diimine hydrochloride and N-hydroxysuccinimide, adjusting the pH, stirring while reacting, and separating in a centrifugal manner, so as to obtain amino polyethylene glycol modified nano graphene oxide; dispersing amino polyethylene glycol modified nano graphene oxide into a solution, adding 1-ethyl-(3-dimethyl aminopropyl) carbonyl diimine hydrochloride and N-hydroxysuccinimide, dropwise adding an insulin derivative, and stirring while reacting, so as to obtain the amino polyethylene glycol functionalized nano graphene oxide supported insulin derivative material. The material provided by the invention can significantly inhibit human pancreas islet amyloid protein aggregation.

The invention relates to a chemical total synthesis method of novel bromophenol-oxazole PTP1B and its use in a drug for treatment on diabetes mellitus type 2. The PTP1B inhibitor has a structural formula shown in the description. The compound improves insulin receptor sensibility through inhibiting the activity of protein tyrosine phosphatase 1B and has good treatment effects on insulin resistance-type diabetes mellitus type 2.

Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced β-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (T2D).

The invention belongs to the technical field of traditional Chinese medicine and relates to qi supplementing and yin nourishing glycemic control pills for treating qi and yin deficiency of diabetes mellitus type 2 and a preparation method of the pills. The pills are prepared from a pulverization group and a decoction group in the following weight ratio: the pulverization group is prepared from thefollowing components in a weight ratio: 135-150 g of radix pseudostellariae, 120-140 g of common macrocarpium fruit, 45-65 g of fructus schisandrae, 120-140 g of raw rhizoma dioscoreae, 120-140 g oforiental waterplantain rhizome, 120-140 g of poria cocos, 40-70 g of radix ophiopogonis and 130-145 g of dry radix rehmanniae recens; the decoction group is prepared from the following components in aweight ratio: 190-210 g of raw radix astragali, 40-50 g of fried rhizoma atractylodis, 35-45 g of fried rhizoma atractylodis macrocephalae, 135-148 g of radix salviae miltiorrhizae, 50-80 g of friedfructus aurantii and 15-30 g of rhizoma cimicifugae pieces. The medicines are scientific and reasonable in compatibility, supplement one another and jointly have the effects of supplementing qi and nourishing yin when mixed for use, qi is restored and yin is coordinated, qi and yin are in harmony, and accordingly, glycemic control is realized. The preparation process of the drug is simple, the drug is convenient to apply and has remarkable effect and no side effect, and relapse is avoided.

The present invention relates to the use of sphingolipids for the preparation of a food item, a food supplement and / or a medicament for the treatment of insulin resistance, diabetes mellitus type 2 and / or metabolic syndrome. In particular, the invention relates to the use of a sphingolipid with the general formula (I):whereinZ is R3 or —CH(OH)—R3;A is sulphate, sulphonate, phosphate, phosphonate or —C(O)O—;R1 is H, hydroxyl, alditol, aldose, an alcohol, C1-C6 alkyl or amino acid;R2 is H or unsaturated or saturated (C1-C30) alkyl chain;R3 is unsaturated or saturated (C1-C30) alkyl chain;Q1 is a primary amine group (—NH2), secondary amine group (—NH—) or an amide group (—NH—CO—); andt is 0 or 1, or a precursor, a derivative or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention and / or treatment of a disorder selected from the group consisting of insulin resistance, diabetes type 2 and metabolic syndrome.